Bladder perfusion pharmaceutical composition, preparation method therefor and application thereof
US-2024398841-A1 · Dec 5, 2024 · US
Method for treating cancer using a selenourea-coordinated gold(I)-carbene complex
US10507213B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10507213-B2 |
| Application number | US-201715794044-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 26, 2017 |
| Priority date | Oct 26, 2017 |
| Publication date | Dec 17, 2019 |
| Grant date | Dec 17, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Gold(I)-carbene complexes having a selenium donor ligand with anti-cancer activity and a method of treating cancer. Methods of treating cancer comprising administering the complexes are also provided.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a proliferative disease, disorder or condition in a subject, comprising: administering to a subject in need thereof a composition comprising [Au(Ipr)(Seu)][anion] (1), wherein Ipr is 1,3-bis(2,6-di-isopropylphenyl)imidazol-2-ylidene, and Seu is selenourea, as described by Formula (3): wherein the proliferative disease, disorder, or condition is breast cancer, colon cancer or lung cancer. 2. The method of claim 1 , wherein the anion is PF 6 − . 3. The method of claim 1 , wherein the proliferative disease, disorder, or condition is breast cancer. 4. The method of claim 1 , wherein the proliferative disease, disorder, or condition is colon cancer. 5. The method of claim 1 , wherein the proliferative disease, disorder, or condition is lung cancer.
Assignees
Inventors
Classifications
Compounds containing heavy metals · CPC title
- A61K31/555Primary
containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- C07F1/00Primary
Compounds containing elements of Groups 1 or 11 of the Periodic Table · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10507213B2 cover?
- Gold(I)-carbene complexes having a selenium donor ligand with anti-cancer activity and a method of treating cancer. Methods of treating cancer comprising administering the complexes are also provided.
- Who is the assignee on this patent?
- Univ King Fahd Pet & Minerals
- What technology area does this patent fall under?
- Primary CPC classification A61K31/555. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).